Literature DB >> 35939772

Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies.

Jerold Loh1, Yvonne Li En Ang1, Amit Jain2, Joe Yeong3,4,5, Raghav Sundar1,6,7,8,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35939772      PMCID： PMC9384951          DOI： 10.1200/PO.22.00208

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  71 in total

1.  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.

Authors:  David S Hong; Steven G DuBois; Shivaani Kummar; Anna F Farago; Catherine M Albert; Kristoffer S Rohrberg; Cornelis M van Tilburg; Ramamoorthy Nagasubramanian; Jordan D Berlin; Noah Federman; Leo Mascarenhas; Birgit Geoerger; Afshin Dowlati; Alberto S Pappo; Stefan Bielack; François Doz; Ray McDermott; Jyoti D Patel; Russell J Schilder; Makoto Tahara; Stefan M Pfister; Olaf Witt; Marc Ladanyi; Erin R Rudzinski; Shivani Nanda; Barrett H Childs; Theodore W Laetsch; David M Hyman; Alexander Drilon
Journal:  Lancet Oncol       Date:  2020-02-24       Impact factor: 41.316

2.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Authors:  Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

3.  Addressing genetic tumor heterogeneity through computationally predictive combination therapy.

Authors:  Boyang Zhao; Justin R Pritchard; Douglas A Lauffenburger; Michael T Hemann
Journal:  Cancer Discov       Date:  2013-12-06       Impact factor: 39.397

4.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

5.  Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Authors:  Ultan McDermott; A John Iafrate; Nathanael S Gray; Toshi Shioda; Marie Classon; Shyamala Maheswaran; Wenjun Zhou; Hwan Geun Choi; Shannon L Smith; Lori Dowell; Lindsey E Ulkus; Georgiana Kuhlmann; Patricia Greninger; James G Christensen; Daniel A Haber; Jeffrey Settleman
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

Authors:  Aurélien Marabelle; Marwan Fakih; Juanita Lopez; Manisha Shah; Ronnie Shapira-Frommer; Kazuhiko Nakagawa; Hyun Cheol Chung; Hedy L Kindler; Jose A Lopez-Martin; Wilson H Miller; Antoine Italiano; Steven Kao; Sarina A Piha-Paul; Jean-Pierre Delord; Robert R McWilliams; David A Fabrizio; Deepti Aurora-Garg; Lei Xu; Fan Jin; Kevin Norwood; Yung-Jue Bang
Journal:  Lancet Oncol       Date:  2020-09-10       Impact factor: 41.316

7.  Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

Authors:  Benjamin J Solomon; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Yiyun Tang; Keith D Wilner; Fiona Blackhall; Tony S Mok
Journal:  J Clin Oncol       Date:  2018-05-16       Impact factor: 44.544

8.  Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer.

Authors:  Johanna S M Mattsson; Hans Brunnström; Verena Jabs; Karolina Edlund; Karin Jirström; Stephanie Mindus; Linnéa la Fleur; Fredrik Pontén; Mats G Karlsson; Christina Karlsson; Hirsh Koyi; Eva Brandén; Johan Botling; Gisela Helenius; Patrick Micke; Maria A Svensson
Journal:  BMC Cancer       Date:  2016-08-05       Impact factor: 4.430

Review 9.  Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects.

Authors:  Zhenya Tang; Lu Wang; Guilin Tang; L Jeffrey Medeiros
Journal:  Int J Mol Sci       Date:  2019-08-13       Impact factor: 5.923

Review 10.  Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.

Authors:  Mathieu Chevallier; Maxime Borgeaud; Alfredo Addeo; Alex Friedlaender
Journal:  World J Clin Oncol       Date:  2021-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.